KPTI
Karyopharm Therapeutics Inc. NASDAQ Listed Nov 6, 2013$8.86
Mkt Cap $75.6M
52w Low $3.65
70.9% of range
52w High $10.99
50d MA $8.04
200d MA $6.73
P/E (TTM)
-0.5x
EV/EBITDA
-2.8x
P/B
—
Debt/Equity
-0.8x
ROE
66.9%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
0.40
50d MA
$8.04
200d MA
$6.73
Avg Volume
1.0M
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
85 Wells Avenue · Newton, MA 02459 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | -2.26 | -3.60 | -59.3% | 8.94 | +0.4% | -4.0% | +9.6% | -1.6% | +4.5% | +0.0% | — |
| Nov 3, 2025 | AMC | -3.47 | -3.82 | -10.1% | 6.07 | -1.2% | -6.9% | -5.1% | -2.6% | -1.1% | +5.4% | — |
| Aug 11, 2025 | AMC | -3.80 | -4.32 | -13.7% | 3.77 | -0.8% | +6.6% | +10.7% | +4.5% | +27.3% | -5.6% | — |
| May 12, 2025 | AMC | -4.21 | -2.77 | +34.2% | 6.15 | -6.5% | -20.0% | -1.4% | +12.2% | -2.2% | -3.6% | — |
| Feb 19, 2025 | AMC | -3.90 | -3.60 | +7.7% | 9.00 | +1.9% | +1.7% | -1.9% | -0.6% | -4.3% | +15.0% | — |
| Nov 5, 2024 | AMC | -4.05 | -3.90 | +3.7% | 12.69 | +0.5% | +4.8% | -0.5% | -0.6% | +5.2% | -2.6% | — |
| Aug 6, 2024 | AMC | -4.35 | -3.00 | +31.0% | 12.60 | +1.2% | -3.4% | +3.4% | -3.4% | +0.6% | +2.2% | — |
| May 8, 2024 | AMC | -4.95 | -4.80 | +3.0% | 15.30 | +2.0% | +4.9% | +1.9% | +2.8% | -2.7% | +3.7% | — |
| Feb 29, 2024 | AMC | -4.35 | -5.40 | -24.1% | 17.40 | +2.6% | +2.1% | +10.6% | -4.9% | +6.8% | +15.0% | — |
| Nov 2, 2023 | AMC | -4.20 | -4.50 | -7.1% | 11.42 | +1.7% | +16.9% | -1.1% | -9.2% | -6.2% | -7.6% | — |
| Aug 2, 2023 | AMC | -5.10 | -4.35 | +14.7% | 26.85 | +0.6% | +1.1% | -5.0% | -6.4% | +2.5% | -1.8% | — |
| May 4, 2023 | AMC | -5.10 | -4.50 | +11.8% | 41.55 | +2.5% | -2.2% | -7.7% | -0.4% | +8.4% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.66 | $8.99 | +3.8% | +0.0% | -0.7% | -2.3% | -1.1% | +5.5% |
| Mar 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.48 | $5.40 | -1.5% | -3.3% | +5.1% | +4.5% | +1.2% | +7.3% |
| Mar 25 | Baird | Maintains | Outperform → Outperform | — | $5.44 | $5.36 | -1.5% | -4.2% | +6.9% | -1.6% | -3.3% | +5.1% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.44 | $5.36 | -1.5% | -4.2% | +6.9% | -1.6% | -3.3% | +5.1% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.40 | $9.64 | +2.6% | -1.6% | +4.5% | +0.0% | +3.7% | +0.4% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $6.07 | $6.00 | -1.2% | -6.9% | -5.1% | -2.6% | -1.1% | +5.4% |
| Oct 13 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $5.50 | $6.01 | +9.3% | +2.2% | +2.7% | +3.1% | +1.3% | -1.7% |
| Oct 9 | Baird | Maintains | Outperform → Outperform | — | $5.90 | $5.61 | -4.9% | -1.4% | -5.5% | +2.2% | +2.7% | +3.1% |
| Oct 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.90 | $5.61 | -4.9% | -1.4% | -5.5% | +2.2% | +2.7% | +3.1% |
| Aug 12 | Baird | Maintains | Outperform → Outperform | — | $3.77 | $3.74 | -0.8% | +6.6% | +10.7% | +4.5% | +27.3% | -5.6% |
| Jul 16 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $4.24 | $4.22 | -0.5% | -1.4% | -2.6% | -5.4% | +4.4% | -3.2% |
| May 13 | Baird | Maintains | Outperform → Outperform | — | $6.15 | $5.75 | -6.5% | -20.0% | -1.4% | +12.2% | -2.2% | -3.6% |
| May 13 | RBC Capital | Maintains | Outperform → Outperform | — | $6.15 | $5.75 | -6.5% | -20.0% | -1.4% | +12.2% | -2.2% | -3.6% |
| May 13 | Barclays | Maintains | Overweight → Overweight | — | $6.15 | $5.75 | -6.5% | -20.0% | -1.4% | +12.2% | -2.2% | -3.6% |
| Mar 3 | Baird | Maintains | Outperform → Outperform | — | $7.95 | $7.83 | -1.5% | -8.8% | -12.1% | -3.9% | +1.6% | +10.8% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.55 | $8.78 | +2.7% | +15.0% | -15.1% | -4.8% | -8.8% | -12.1% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.00 | $9.17 | +1.9% | +1.7% | -1.9% | -0.6% | -4.3% | +15.0% |
| Feb 20 | RBC Capital | Maintains | Outperform → Outperform | — | $9.00 | $9.17 | +1.9% | +1.7% | -1.9% | -0.6% | -4.3% | +15.0% |
| Feb 10 | RBC Capital | Maintains | Outperform → Outperform | — | $9.47 | $9.75 | +3.0% | -1.4% | -4.0% | -2.0% | +4.1% | +1.1% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.50 | $10.05 | +5.8% | +0.4% | +9.7% | -5.4% | +4.0% | -2.9% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.69 | $12.75 | +0.5% | +4.8% | -0.5% | -0.6% | +5.2% | -2.6% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.69 | $12.75 | +0.5% | +4.8% | -0.5% | -0.6% | +5.2% | -2.6% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.85 | $14.85 | +0.0% | -8.8% | +3.3% | -9.4% | +4.8% | -0.5% |
| Aug 7 | Baird | Maintains | Outperform → Outperform | — | $12.60 | $12.75 | +1.2% | -3.4% | +3.4% | -3.4% | +0.6% | +2.2% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $12.60 | $12.75 | +1.2% | -3.4% | +3.4% | -3.4% | +0.6% | +2.2% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.60 | $12.75 | +1.2% | -3.4% | +3.4% | -3.4% | +0.6% | +2.2% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.60 | $14.29 | -2.1% | -10.9% | -6.0% | -1.9% | +3.5% | -1.1% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.54 | $14.70 | +1.1% | +1.9% | -6.1% | +7.3% | -2.2% | -1.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.30 | $15.60 | +2.0% | +4.9% | +1.9% | +2.8% | -2.7% | +3.7% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.40 | $17.85 | +2.6% | +2.1% | +10.6% | -4.9% | +6.8% | +15.0% |
| Nov 3 | RBC Capital | Maintains | Outperform → Outperform | — | $11.42 | $11.61 | +1.7% | +16.9% | -1.1% | -9.2% | -6.2% | -7.6% |
| Nov 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.42 | $11.61 | +1.7% | +16.9% | -1.1% | -9.2% | -6.2% | -7.6% |
| Aug 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.80 | $25.80 | +0.0% | -6.4% | +2.5% | -1.8% | +3.1% | +1.8% |
| Aug 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $26.85 | $27.00 | +0.6% | +1.1% | -5.0% | -6.4% | +2.5% | -1.8% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.85 | $27.00 | +0.6% | +1.1% | -5.0% | -6.4% | +2.5% | -1.8% |
| Aug 3 | RBC Capital | Maintains | Outperform → Outperform | — | $26.85 | $27.00 | +0.6% | +1.1% | -5.0% | -6.4% | +2.5% | -1.8% |
| Jul 26 | Wedbush | Maintains | Neutral → Neutral | — | $23.85 | $23.25 | -2.5% | +8.8% | -2.3% | +6.5% | +0.0% | +0.0% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.85 | $23.25 | -2.5% | +8.8% | -2.3% | +6.5% | +0.0% | +0.0% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.95 | $27.30 | +19.0% | -2.6% | +7.4% | +0.6% | +3.1% | -1.8% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.55 | $42.60 | +2.5% | -2.2% | -7.7% | -0.4% | +8.4% | -1.9% |
| May 5 | Baird | Maintains | Outperform → Outperform | — | $41.55 | $42.60 | +2.5% | -2.2% | -7.7% | -0.4% | +8.4% | -1.9% |
| May 5 | RBC Capital | Maintains | Outperform → Outperform | — | $41.55 | $42.60 | +2.5% | -2.2% | -7.7% | -0.4% | +8.4% | -1.9% |
| Apr 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.25 | $62.70 | +0.7% | -0.2% | -8.2% | +7.6% | +0.0% | -8.3% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.00 | $48.30 | +0.6% | -0.6% | +0.0% | -5.7% | +1.3% | -0.7% |
| Feb 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.90 | $54.75 | -0.3% | -1.9% | -1.1% | -9.9% | -0.6% | +0.0% |
| Jan 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $46.95 | $47.55 | +1.3% | +1.6% | -3.1% | +7.1% | +1.2% | +5.1% |
| Jan 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.05 | $48.30 | +4.9% | +8.8% | +0.9% | -3.6% | +2.2% | -3.0% |
| Jan 10 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $42.60 | $42.45 | -0.4% | +1.1% | +3.1% | +3.0% | +8.2% | -5.8% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.60 | $42.45 | -0.4% | +1.1% | +3.1% | +3.0% | +8.2% | -5.8% |
| Nov 4 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $68.10 | $75.75 | +11.2% | +4.4% | +8.6% | +3.9% | +1.1% | +6.1% |
No insider trades available.
8-K
Unknown — 8-K Filing
Karyopharm's runway extending to Q3 2026 suggests manageable near-term solvency, but investors should monitor burn rate closely as the company relies on product revenue growth to avoid future dilutive financing.
Mar 27
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
KPTI's equity issuance agreement with RA Capital likely dilutes existing shareholders but provides needed capital for operations or clinical development, a mixed signal for near-term stock performance.
Mar 24
8-K · 5.02
!!! Very High
Zevra Therapeutics, Inc. -- 8-K 5.02: Executive Change
Zevra Therapeutics appointed Justin Renz as Chief Financial Officer while he resigned from the board, effective March 9, 2026, signaling potential leadership restructuring.
Mar 9
8-K · 8.01
!! High
Karyopharm Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Karyopharm Therapeutics secured a forbearance agreement delaying debt obligations until late 2026, contingent on completing a capital raise to improve liquidity and avoid default.
Mar 3
8-K
Karyopharm Therapeutics Inc. -- 8-K Filing
I cannot provide a meaningful investor analysis from this filing, as the summary contains only technical XBRL metadata and reference information rather than substantive business details or corporate actions.
Feb 19
8-K
Karyopharm Therapeutics Inc. -- 8-K Filing
Karyopharm Therapeutics reported $115 million in 2025 XPOVIO revenue and guided 2026 total revenue to $130-$150 million, indicating modest growth expectations for its lead oncology drug.
Feb 12
Data updated apr 25, 2026 5:55pm
· Source: massive.com